Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Theranostics 2020 ; 10 (26): 12223-12240 Nephropedia Template TP
Cheng Y; Sun F; Wang L; Gao M; Xie Y; Sun Y; Liu H; Yuan Y; Yi W; Huang Z; Yan H; Peng K; Wu Y; Cao Z
Theranostics 2020[]; 10 (26): 12223-12240 PMID33204339show ga
Rationale: Many viral infections are known to activate the p38 mitogen-activated protein kinase (MAPK) signaling pathway. However, the role of p38 activation in viral infection and the underlying mechanism remain unclear. The role of virus-hijacked p38 MAPK activation in viral infection was investigated in this study. Methods: The correlation of hepatitis C virus (HCV) infection and p38 activation was studied in patient tissues and primary human hepatocytes (PHHs) by immunohistochemistry and western blotting. Coimmunoprecipitation, GST pulldown and confocal microscopy were used to investigate the interaction of p38alpha and the HCV core protein. In vitro kinase assays and mass spectrometry were used to analyze the phosphorylation of the HCV core protein. Plaque assays, quantitative real time PCR (qRT-PCR), western blotting, siRNA and CRISPR/Cas9 were used to determine the effect of p38 activation on viral replication. Results: HCV infection was associated with p38 activation in clinical samples. HCV infection increased p38 phosphorylation by triggering the interaction of p38alpha and TGF-beta activated kinase 1 (MAP3K7) binding protein 1 (TAB1). TAB1-mediated p38alpha activation facilitated HCV replication, and pharmaceutical inhibition of p38alpha activation by SB203580 suppressed HCV infection at the viral assembly step. Activated p38alpha interacted with the N-terminal region of the HCV core protein and subsequently phosphorylated the HCV core protein, which promoted HCV core protein oligomerization, an essential step for viral assembly. As expected, SB203580 or the HCV core protein N-terminal peptide (CN-peptide) disrupted the p38alpha-HCV core protein interaction, efficiently impaired HCV assembly and impeded normal HCV replication in both cultured cells and primary human hepatocytes. Similarly, severe fever with thrombocytopenia syndrome virus (SFTSV), herpes simplex virus type 1 (HSV-1) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection also activated p38 MAPK. Most importantly, pharmacological blockage of p38 activation by SB203580 effectively inhibited SFTSV, HSV-1 and SARS-CoV-2. Conclusion: Our study shows that virus-hijacked p38 activation is a key event for viral replication and that pharmacological blockage of p38 activation is an antiviral strategy.
|A549 Cells[MESH]
|Adaptor Proteins, Signal Transducing/metabolism[MESH]
|Animals[MESH]
|COVID-19/*metabolism/virology[MESH]
|Chlorocebus aethiops[MESH]
|Enzyme Activation[MESH]
|HEK293 Cells[MESH]
|Hepacivirus/*metabolism[MESH]
|Hepatitis C/*metabolism/pathology/virology[MESH]
|Hepatocytes/metabolism[MESH]
|Humans[MESH]
|Imidazoles/pharmacology[MESH]
|MAP Kinase Kinase Kinases/metabolism[MESH]
|MAP Kinase Signaling System/drug effects[MESH]
|Mitogen-Activated Protein Kinase 14/antagonists & inhibitors/*metabolism[MESH]
free
free
free
Theranostics 2020 ; 10 (26): 12223-12240
